Meeting
2013 ASCO Annual Meeting
Does EGFR mutation define the histological predominant subtype of lung adenocarcinoma?
Authors
Eri Sugiyama
Division of Thoracic Oncology, National Cancer Center Hospital East, Kashiwa, Japan
Eri Sugiyama , Koichi Goto , Genichiro Ishii , Tomohiro Haruki , Shingo Matsumoto , Shigeki Umemura , Kiyotaka Yoh , Seiji Niho , Hironobu Ohmatsu , Kanji Nagai , Yuichiro Ohe
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Lung Cancer - Non-small Cell Local-regional/Small Cell/Other Thoracic Cancers
Track
Lung Cancer
Sub Track
Local-Regional Non–Small Cell Lung Cancer
Citation
J Clin Oncol 31, 2013 (suppl; abstr 7557)
DOI
10.1200/jco.2013.31.15_suppl.7557
Abstract #
7557
Poster Bd #
22C
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Annual Meeting
Safety and efficacy of osimertinib in patients with NSCLC and uncommon tumoral EGFR mutations: A systematic review and meta-analysis.
First Author: Jonathan N. Priantti
Poster
2013 ASCO Annual Meeting
Correlation of epidermal growth factor receptor (EGFR) mutation profile with computed tomography (CT) imaging features in lung adenocarcinomas.
First Author: Benjamin F. Chu
Poster
2011 ASCO Annual Meeting
Impact of dietary habits on epidermal growth factor receptor (EGFR) mutation status of Japanese patients with lung adenocarcinomas.
First Author: Y. Yamane
Poster
2024 ASCO Annual Meeting
REZILIENT3: Phase 3 study of zipalertinib plus chemotherapy in patients with previously untreated, advanced nonsquamous non-small cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) exon 20 insertions (ex20ins) mutations.
First Author: Helena Alexandra Yu